



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/380488/2023

European Medicines Agency decision P/0351/2023

of 8 September 2023

on the granting of a product specific waiver for encorafenib (Braftovi), (EMEA-001588-PIP04-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Only the English text is authentic.



European Medicines Agency decision

P/0351/2023

of 8 September 2023

on the granting of a product specific waiver for encorafenib (Braftovi), (EMA-001588-PIP04-23) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by Pierre Fabre Médicament on 20 April 2023 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 21 July 2023 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A waiver for encorafenib (Braftovi), all pharmaceutical forms, all routes of administration, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 2

This decision is addressed to Pierre Fabre Médicament, Les Cauquillous, 81500 - Lavar, France.

EMA/PDCO/203913/2023
Amsterdam, 21 July 2023

Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMA-001588-PIP04-23

Scope of the application

Active substance(s):

Encorafenib

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of lung cancer

Pharmaceutical form(s):

All pharmaceutical forms

Route(s) of administration:

All routes of administration

Name/corporate name of the PIP applicant:

Pierre Fabre Médicament

Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Pierre Fabre Médicament submitted to the European Medicines Agency on 20 April 2023 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 22 May 2023.

Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to grant a product-specific waiver for all subsets of the paediatric population and the above mentioned condition(s) in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended occurs only in adult populations.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

Grounds for the granting of the waiver

1. Waiver

1.1. Condition:

Treatment of lung cancer

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- all pharmaceutical forms, all routes of administration;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of melanoma

Authorised indication(s):

- Encorafenib is indicated in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
 - Invented name(s): Braftovi
 - Authorised pharmaceutical form(s): Hard capsule
 - Authorised route(s) of administration: Oral use
 - Authorised via centralised procedure

2. Treatment of colorectal carcinoma

Authorised indication(s):

- Encorafenib is indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy.
 - Invented name(s): Braftovi
 - Authorised pharmaceutical form(s): Hard capsule
 - Authorised route(s) of administration: Oral use
 - Authorised via centralised procedure